Compound | Conc. | Uptake | |||
---|---|---|---|---|---|
hMATE1 | hMATE2-K | ||||
DAPI | [3H]Cimetidine | DAPI | [3H]Cimetidine | ||
mM | %control | ||||
None (control) | 100.0 ± 1.4 | 100.0 ± 3.0 | 100.0 ± 1.5 | 100.0 ± 1.5 | |
Cimetidine | 0.2 | N.D. | N.D. | 24.6 ± 1.6* | 3.1 ± 0.7* |
Clonidine | 0.2 | 45.4 ± 1.3* | 18.4 ± 0.5* | 65.2 ± 3.3* | 24.2 ± 1.2* |
Corticosterone | 0.2 | 34.0 ± 2.0* | 27.6 ± 0.4* | 49.8 ± 2.6* | 13.5 ± 0.5* |
Diphenhydramine | 0.2 | 34.1 ± 1.5* | 23.6 ± 0.9* | 57.2 ± 2.1* | 41.4 ± 1.7* |
Diltiazem | 0.2 | N.D. | 5.8 ± 0.2* | 47.4 ± 2.1* | 33.6 ± 2.2* |
Estrone-3-sulfate | 0.2 | 80.5 ± 2.4* | 65.9 ± 0.6* | 100.8 ± 4.6 | 70.0 ± 2.8* |
Guanidine | 2 | 92.3 ± 2.6 | 92.9 ± 2.8 | 103.8 ± 1.8 | 87.8 ± 0.8* |
Imipramine | 0.2 | 1.0 ± 0.6* | 11.5 ± 0.3* | 19.2 ± 1.4* | 25.9 ± 0.6* |
MPP | 0.2 | 60.6 ± 1.7* | 27.7 ± 0.4* | 82.8 ± 3.6* | 27.3 ± 1.8* |
Nicotinamide | 0.2 | 105.1 ± 2.8 | 106.6 ± 5.1 | 112.0 ± 2.8* | 97.0 ± 1.7 |
NMN | 2 | 111.1 ± 1.8* | 123.4 ± 5.0* | 117.7 ± 4.4* | 78.9 ± 1.5* |
Norepinephrine | 0.2 | 74.9 ± 1.8* | 89.0 ± 1.2* | 67.7 ± 2.9* | 65.3 ± 3.8* |
PAH | 0.2 | 96.6 ± 6.0 | 132.0 ± 3.6* | 105.3 ± 2.0 | 102.6 ± 4.1 |
Procainamide | 0.2 | 96.4 ± 3.0 | 58.2 ± 1.0* | 93.3 ± 3.3 | 30.5 ± 1.3* |
Serotonin | 0.2 | 93.3 ± 2.9 | 44.9 ± 2.0* | 107.2 ± 4.4 | 69.2 ± 4.0* |
TEA | 2 | 54.6 ± 2.7* | 23.6 ± 0.2* | 88.4 ± 1.9* | 27.0 ± 0.2* |
TPP | 0.2 | 12.9 ± 1.6* | 13.0 ± 0.5* | 67.9 ± 3.3* | 26.4 ± 0.3* |
Verapamil | 0.2 | N.D. | 10.8 ± 0.6* | 10.9 ± 1.4* | 11.8 ± 0.7* |
MPP, 1-methyl-4-phenylpyridinium; NMN, N-methylnicotinamide; PAH, p-aminohippurate; TPP, thiamine pyrophosphate; N.D., not detected.
↵* Significantly different from the value for control at p < 0.05.